Pure red cell aplasia complicating the course of long-standing mantle cell lymphoma

Int J Hematol. 2014 Jun;99(6):777-81. doi: 10.1007/s12185-014-1563-5. Epub 2014 Mar 26.

Abstract

Pure red cell aplasia (PRCA) is a rare cause of severe hypoplastic anemia characterized by profound depletion of erythroid precursors. Although PRCA may be associated with lymphoproliferative diseases, it has never been described in mantle cell lymphoma (MCL). We report what to our knowledge is the first case of a patient with indolent, non-nodal MCL complicated by PRCA. The patient presented with severe hypoproliferative anemia in the setting of a long-standing diagnosis of B-cell chronic lymphocytic leukemia. Bone marrow studies revealed the complete absence of erythroid progenitors. Cyclin D1 positivity on immunohistochemistry, confirmed by a positive FISH for t(11;14) (q13;q32), established the final diagnosis of MCL in conjunction with PRCA. Rituximab monotherapy led to rapid remission of splenomegaly and the leukemic picture, but the patient achieved transfusion independency only with subsequent administration of cyclosporine-A, and remained so during the subsequent 15 months despite the gradual disease recurrence.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Blood Transfusion
  • Bone Marrow / pathology
  • Female
  • Humans
  • Immunohistochemistry
  • Immunophenotyping
  • Lymphoma, Mantle-Cell / complications*
  • Lymphoma, Mantle-Cell / diagnosis
  • Lymphoma, Mantle-Cell / drug therapy
  • Red-Cell Aplasia, Pure / complications*
  • Red-Cell Aplasia, Pure / diagnosis
  • Red-Cell Aplasia, Pure / therapy
  • Rituximab
  • Splenomegaly
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab